This is a release of management information for anonymous summary data for those patients that have been identified on the Shielded Patient List (SPL). Its purpose is to make the summary data available to a wider audience, as open data, to enable a broad base of users to perform analysis from it. The purpose behind releasing this data is to present regional and local data to allow for its use in public health. It will also allow for greater analysis, modelling and planning to be performed using the latest data, to aid in the response to the pandemic. We will update this weekly and we would welcome your feedback to help us develop our open data sets. The data that is published is based on version 74 of the SPL clinical methodology, with the data extracted as at 21 September 2021.

The Chief Medical Officer (CMO) for England, working with the CMOs of the devolved nations and other senior clinicians, commissioned NHS Digital to produce a list of people at “high risk” of complications from COVID-19, who should be shielded for at least 12 weeks. The CMO for Wales commissioned a collaboration of national bodies in Wales (NWIS, DU, NWSSP, PHW) to identify “high risk” people for the Welsh population, based largely on the NHS Digital methodology. This list is referred to as the Shielded Patient List (SPL).

The “high risk” list was defined as a subset of a wider group of people who may be “at risk”. Specific advice applies to these groups, currently this advice is: • “At Risk” – large group normally at risk from the flu - should practice strict social distancing • “At high risk” – a smaller sub-group (circa 70k), defined by CMO – should practice complete social “shielding” NHS Digital have described the methodology that has been used to identify patients who meet the high risk criteria due to their inclusion in one or more of the disease groups.

As there are differences in some of the systems used across the devolved nations, nuanced differences in application and interpretation of CMO guidance, this document describes the Welsh methodology.

https://nwis.nhs.wales/coronavirus/coronavirus-content/coronavirus-documents/covid-19-high-risk-shielded-patient-list-identification-methodology/

The dataset time coverage ends in August 2022.

The Chief Medical Officer (CMO) for England, working with the CMOs of the devolved nations and other senior clinicians, commissioned NHS Digital to produce a list of people at “high risk” of complications from COVID-19, who should be shielded for at least 12 weeks. The CMO for Wales commissioned a collaboration of national bodies in Wales (NWIS, DU, NWSSP, PHW) to identify “high risk” people for the Welsh population, based largely on the NHS Digital methodology. This list is referred to as the Shielded Patient List (SPL).

The “high risk” list was defined as a subset of a wider group of people who may be “at risk”. Specific advice applies to these groups, currently this advice is: • “At Risk” – large group normally at risk from the flu - should practice strict social distancing • “At high risk” – a smaller sub-group (circa 70k), defined by CMO – should practice complete social “shielding” NHS Digital have described the methodology that has been used to identify patients who meet the high risk criteria due to their inclusion in one or more of the disease groups.

As there are differences in some of the systems used across the devolved nations, nuanced differences in application and interpretation of CMO guidance, this document describes the Welsh methodology.

https://nwis.nhs.wales/coronavirus/coronavirus-content/coronavirus-documents/covid-19-high-risk-shielded-patient-list-identification-methodology/

Dataset received it's final update in March 2022

List of high-risk people advised to self-isolate during Covid pandemic.

CVD-COVID-UK, co-ordinated by the British Heart Foundation (BHF) Data Science Centre (https://bhfdatasciencecentre.org/), is one of the NIHR-BHF Cardiovascular Partnership’s National Flagship Projects.

CVD-COVID-UK aims to understand the relationship between COVID-19 and cardiovascular diseases through analyses of de-identified, pseudonymised, linked, nationally collated health datasets across the four nations of the UK. The consortium has over 400 members across more than 50 institutions including data custodians, data scientists and clinicians, all of whom have signed up to an agreed set of principles with an inclusive, open and transparent ethos.

Approved researchers access data within secure trusted/secure research environments (TREs/SDEs) provided by NHS England (England), the National Safe Haven (Scotland), the Secure Anonymised Information Linkage (SAIL) Databank (Wales) and the Honest Broker Service (Northern Ireland). A dashboard of datasets available in each nation’s TRE can be found here: https://bhfdatasciencecentre.org/areas/cvd-covid-uk-covid-impact/

This dataset represents the linked datasets in SAIL Databank’s TRE for Wales and contains the following datasets: • Welsh Longitudinal GP Dataset - Welsh Primary Care (Daily COVID codes only) (GPCD) • Welsh Longitudinal General Practice Dataset (WLGP) - Welsh Primary Care • Critical Care Dataset (CCDS) • Emergency Department Dataset Daily (EDDD) • Emergency Department Dataset (EDDS) • Outpatient Database for Wales (OPDW) • Outpatient Referral (OPRD) • Patient Episode Dataset for Wales (PEDW) • COVID-19 Test Results (PATD) • COVID-19 Test Trace and Protect (CTTP) - Legacy • COVID-19 Shielded People List (CVSP) • SARS-CoV-2 viral sequencing data (COG-UK data)-Lineage/Variant Data-Wales (CVSD) • Covid Vaccination Dataset (CVVD) • Annual District Death Daily (ADDD) • Annual District Death Extract (ADDE) • COVID-19 Consolidated Deaths (CDDS) • Intensive Care National Audit and Research Centre (ICCD) - Legacy - COVID only • Intensive Care National Audit and Research Centre (ICNC) • Welsh Dispensing Dataset (WDDS) - Legacy • Annual District Birth Extract (ADBE) • Maternity Indicators Dataset (MIDS) • National Community Child Health Database (NCCHD) • Care Home Dataset (CARE) • Congenital Anomaly Register and Information Service (CARS) • Referral to Treatment Times (RTTD) • SAIL Dementia e-Cohort (SDEC) • Welsh Ambulance Services NHS Trust (WASD) • Welsh Demographic Service Dataset (WDSD) • Welsh Results Reports Service (WRRS) • ONS 2011 Census Wales (CENW)

Unequal impact of COVID-19: BAME disproportionality The shielded population are those that have been defined by Government on medical grounds as medically vulnerable due to a clinical condition that puts them at High risk of developing complications from COVID-19 infection.

Those recommended to shield include: • Organ transplant recipients • Pregnant women with congenital heart conditions • Those with rare diseases such as homozygous sickle cell, SCID and others • Those on immunosuppression therapies • People with specific cancers or those with cancer undergoing chemo/radiotherapy.

Camden has so far received the contact details of almost 8,000 residents identified by central Government, with more records likely in future.

The details received do not contain the personal characteristics of those on the list, although we have received an overview from North Central London NHS. (note: above is broken down into shielder’s location and BAME ward profile, shielding population by ethnicity, shielded food need and dietary requirements).